Drug Profile
PF 06952229
Alternative Names: PF-06952229Latest Information Update: 27 Jul 2022
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action Transforming growth factor beta type I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 14 Jul 2022 Pfizer terminates phase I trial in Solid tumours in the US due to strategic considerations (NCT03685591)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO)